Anti-GCC Antibodies and CARs for Immunotherapy

USPTO published application US20260091061A1 covering anti-GCC single domain antibodies (VHH domain antibodies) and chimeric antigen receptors (CARs) comprising an extracellular antigen binding domain, transmembrane domain, and intracellular signaling domain for immune cell transduction. The constructs target GCC (guanylate cyclase C) and are intended for cancer immunotherapy applications including treatment of GCC-expressing tumors. The filing includes comprehensive CPC classifications spanning A61K, C07K, and C12N technical areas.\n\nThis is a routine patent publication with no compliance deadlines, enforcement actions, or regulatory filing requirements. Biotechnology and pharmaceutical companies developing GCC-targeting immunotherapies should review the published claims for potential freedom-to-operate concerns. Inventors and applicants may monitor prosecution of this application through USPTO systems. No action is required for compliance purposes.